Analyst
Cantor Fitzgerald
Equibles does not estimate personal net worth.
Prakhar Agrawal is recorded as Analyst at Cantor Fitzgerald. Prakhar Agrawal has spoken on 6 earnings calls across 4 companies, most recently for Tg Therapeutics, Inc. on November 9, 2026. Those appearances were for Ardelyx, Inc. (ARDX), Travere Therapeutics, Inc. (TVTX), Tg Therapeutics, Inc. (TGTX) and Madrigal Pharmaceuticals, Inc. (MDGL). The companies whose calls Prakhar Agrawal spoke on are classified in the Healthcare sector.
“Maybe firstly, if you can talk about the 340B exposure from BreaMV IV and given the expected policy changes next year around 340B pricing, what could be the potential impact there on BreaMV?”
“So maybe on Israel in 2027, I guess if you can comment on how we should think about access and contracting, given that something that you had discussed before will be more prevalent for Israel going forward, and maybe what does it mean for the evolution of growth to net?”
“Thank you so much for taking my questions, and congrats, Eric, as well, and my wishes to you.”
“Please go ahead. hi uh thank you for taking my questions and congrats on the quarter uh so maybe going back to your comments on faster uptake than eigen uh when i go back to the eigen launch in the first few full quarters you had 400 to 450 uh patient start forms is that how should we think about the uptake for fsgs…”
“Maybe firstly on exposure I mean maybe I missed this but I did not hear you reiterate the long-term guide of 750 million.”
Cantor Fitzgerald
Analyst
Source not stated
ARDX
Biotechnology · Healthcare
